<DOC>
	<DOC>NCT01524406</DOC>
	<brief_summary>This is a safety and tolerability study investigating the effect of HPP593 in healthy volunteers during and after limb immobilization.</brief_summary>
	<brief_title>Safety Study of HPP593 in Subjects During and After Limb Immobilization</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Hypokinesia</mesh_term>
	<criteria>Nonsmoking. Subjects must be in good health, as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical test results. Not restricted to a wheelchair or confined to a bed. Weight ≥ 50.0 kg. BMI between 18 and 27.5 kg/m2, inclusive, at the time of screening. Any of the following abnormalities at Screening Visit and Baseline: Fasting glucose &gt; 110 mg/dL (Screening visit only). Serum creatinine &gt; 1.5 mg/dL. If serum creatinine is &gt;1.5 mg/dL and creatinine clearance is &gt;60 mL/min, the subject need not be excluded Troponin I level above the upper limit of normal (ULN) Liver function tests (LFTs) &gt; 1.5x ULN Evidence of significant organ system dysfunction (e.g. diabetes, cardiovascular disease, cirrhosis, hypogonadism, hypo or hyperthyroidism; hypertension) Any fluctuations in weight (no more than ± 2% of body weight) by subject self report in the 3 months prior to the Screening Visit. Has received HPP593 in a previous clinical trial. Smoking within 6 month prior to Day 1. Michigan Alcohol Screening Test score greater than 2.</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Muscle Atrophy</keyword>
</DOC>